LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.91m
- $0.22m
- $0.17m
U.S. STOCKS ON THE MOVE-Modular Medical, Beazer Homes, oil firms
Lisata climbs on orphan drug status for bile duct cancer candidate
Lisata Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Lisata Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview
Brief: Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Brief: Lisata Therapeutics Announces Full Enrollment Of Pancreatic Cancer Cohort Of Cendifox Trial
Brief: Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From European Medicines Agency
Lisata Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Lisata Therapeutics Files For Mixed Shelf Offering Of Up To $150 Million - SEC Filing
Brief: Lisata Therapeutics' Cancer Drug Gets US FDA Orphan Drug Designation
Lisata Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Lisata Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Lisata Therapeutics Announces First Patient Treated In Phase 2A Trial Of Lsta1
Brief: Lisata Therapeutics Announces Completion Of Enrollment In Phase 2B Ascend Trial Of Lsta1
Lisata Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Lisata Therapeutics Q3 EPS USD -0.65
Lisata Therapeutics Inc expected to post a loss of 93 cents a share - Earnings Preview
Brief: Lisata Therapeutics Report First Patient Treated in Cholangiocarcinoma Cohort Of The BOLSTER Trial Of LSTA1